AstraZeneca’s Tagrisso reduced the risk of death by nearly half in patients with early-stage EGFR-mutated lung cancer, with almost 80% of treated patients alive eight years after surgery, new Phase III data show.

 

AstraZeneca’s Tagrisso (osimertinib) has demonstrated a sustained overall survival benefit eight years after treatment in patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), according to updated results from the global Phase III ADAURA trial.

 

The findings, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul and simultaneously published in the Journal of Thoracic Oncology, represent the longest survival follow-up reported from a global Phase III trial in this treatment setting.

 

In the primary population of patients with Stage II-IIIA disease, Tagrisso reduced the risk of death by 47% compared with placebo, with an overall survival hazard ratio of 0.53. At eight years, an estimated 74% of patients receiving Tagrisso were alive, compared with 58% on placebo.

 

Across the broader Stage IB-IIIA population, Tagrisso reduced the risk of death by 48%, with an overall survival hazard ratio of 0.52. The estimated eight-year survival rate was 79% with Tagrisso versus 64% with placebo.

 

The survival benefit was observed across all predefined patient subgroups.

 

Roy S. Herbst, Director at Dartmouth Cancer Center, and principal investigator in the ADAURA Phase III trial, said: “These ADAURA findings show patients continue to experience meaningful, long-term benefit following early intervention with adjuvant osimertinib, with a 16 per cent point improvement in overall survival at eight years versus placebo. 

 

"This is especially impressive given high rates of crossover to osimertinib following disease recurrence. This durable overall survival benefit reinforces the importance of prioritising EGFR testing at diagnosis so as many patients as possible can benefit from this transformative therapy.”

 

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “ADAURA continues to set new benchmarks in early-stage EGFR-mutated lung cancer, with nearly 80 per cent of patients treated with adjuvant Tagrisso alive at eight years. These results underscore the importance of treating early and reinforce Tagrisso as the adjuvant standard of care and backbone therapy across stages of the disease.”